CIFFREO Data Discussion - 10 OCT 2024 EM USA DMD 0099

Pfizer recently provided this video updating the results from their Phase 3 micro-dystrophin gene therapy trial, CIFFREO, which were presented on October 12, 2024 at the World Muscle Society Conference in Prague. In this video, Francesco Muntoni, Chair of the CIFFREO trial steering committee, and Dan Levy, who leads DMD Clinical Research at Pfizer review the data--which showed no statistically significant improvements in individuals receiving the experimental micro-dystrophin gene therapy--and have a thoughtful discussion about the implications of the findings.
While we’re disappointed with the results of the trial, we appreciate Pfizer’s continued transparency to share as much information as possible with the whole community.
#genetherapy #dmd #duchenne #musculardystrophy

[@digitalbusinessbysohel]

informative

[@jaidebbakshi7707]

Very straight forward.

[@ShejialMaurya]

Goodsir